Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer

  • Technology appraisal guidance
  • TA639
  • Published: 
Commercial discussions have progressed and the appraisal has resumed.